Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Plenary Session:  Innovative Pricing Pricing Models: The Future is Now, 2016 MassBio Annual Meeting  03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta Hotel, Cambridge, MA

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

covers in REAL TIME

2016 MassBio Annual Meeting  03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta Hotel, Cambridge, MA

 In Attendance, steaming LIVE using Social Media

Aviva Lev-Ari, PhD, RN

Editor-in-Chief

http://pharmaceuticalintelligence.com

Director & Founder

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

https://www.massbio.org/events/2016-massbio-annual-meeting-1120

2016 MassBio Annual Meeting  03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta, Cambridge MA

http://pharmaceuticalintelligence.com/2016/03/02/2016-massbio-annual-meeting-03312016-800-am-04012016-300-pm-royal-sonesta-cambridge-ma/

Plenary Session:  Innovative Pricing Pricing Models: The Future is Now

• Laurie Bartlett Keating, Senior Vice President, Counsel, Alnylam

1. Pioneed in value-based Pricing models
2. innovating approaches
3. facilitate access for Total value
4. Ecosystem: Payers, payers, transformative medicine
5. simplification
6. Payers want dialog, variability in outcome
7. experiments free trial fro all MS no inclusion of MedicCare and MedicAid – 60 days  Payers did not pay, 60% converted into paying Patient – extended access not shared costs
8. 3 Parts of Phase I  – inhibitory antibodies developed
9. target reimbursement  – businesses can’t get broke, ObamaCare brought some player to hard time
10. engagement with Payer on Endpoints publish data vs Sales force of Pharme going to Prescribers
11. Novartis access Payers before the drug is available $5 Billion drug to benefit patients
12. consolidate view on Patient vs. FDA reviewer
13. Grants from Public Institutions, Hoe benefits are quantified by European vs US regulatory — What is success Pain tolerance, age,
14. Adherence with protocol of treatment if 4 times a year, deliver better care and capture data simultaneous with quality of life for the Patient
15. bring transformative medicine forward vs me too
16. Vertex – HCV drug, CF via acquisition in San Diego
17. Genomics date will bring smarter therapies, small molecure – exclusivity during Patent then becomes generics for generation and other regions on the Globe

• Sue Hager, Vice President, Corporate Communications and Government Affairs, Foundation Medicine

1. molecular information company – molecular alteration affecting tumor by genomics permutation molecular thumb print
2. 70,000 molecules for precision diagnostics affecting diagnostics and pricing
3. Patient is the center develop models for optimizinf outcomes,
4. last 5 yeard progress in Cancer outcome more significant than the ones in last 50 years
5. big data, bioinformatics Big Pharma looks at Probabilities in populations of patients
6. Pharma extract costs
7. Payers want to own the dat that belong to the Patient
8. information silos, genomics is the holy grail, unite payers and Pharma keep Patient in the middle around the data
9. Foundation Medicien – releases data tostimulate research and Patient access
10. Oncology Payer are innovatintor in Big Data and reimbursement of targeted treatment
11. Cancer care onlabel off laber – seismic change genomics signature vs histology, genomics signature in lang cancer shows in other types of cancer, no access to drug if no same genomic signature

• Steven Hass, Vice President for Patient Outcomes and Medical Economics, Sanofi Genzyme

1. data for performing devision improved
2. Celll theraphy with long term benefit
3. observing benefits – pay for performance
4. Clinical Trial Design – Innovated designs
5. data collection – what is collected and how
6. What can be shared, penalty on what you do not say
7. big data has benefits for all players
8. 1960 and 1013 same % US spent on Healthcare

• Roger Longman, CEO, Real Endpoint

1. Payers are many and make money differently: Exchange vs HMO
2. United HealhtCare is five comapnies each has different models for reimbursement
3. Outcome based Pricing as off label promotion, only id end point is not in the label
4. Cholestrol – Lower LDL nor Lower Cardiac event, No Paye rknown the LDL numbers
5. GSK cannot go to Payers make arguement on economics, unsolicited request by Payers from GSK
6. Economics not on label now allowed to be discussed with Payers
7. Payers are creating options
8. migraine – $ drugs at the same time – contracting strategy? label indication woith advantage on indication
9. Payers driven short term less expensive product Payer will change
10. economically driven organization in Healthcre – Price decrease like generic than cancer drugs looks like
11. Value of drug – how customer looks at value elements

• Peter Pitts, President and Co-Founder, CPMI (Moderator)

1. How is Clinical success been defined
2. innovating pricing model impact clinical trial designed
3. SMDA – last image
4. FDA has Program on success beyond the label
5. Revolving tiering for Pricing
6. deliver innovation and relations to Price
7. SMDA  exclusivity for 5 years only

Questions from the Audience

1. Outraged public on drug pricing
2. Patent law: Europe vs US